Piper Sandler Maintains Neutral on Humacyte, Lowers Price Target to $1

Piper Sandler analyst Allison Bratzel has maintained a Neutral rating on Humacyte (NASDAQ: HUMA) while lowering the price target from $3 to $1. This adjustment reflects a more cautious outlook on the company's performance.